Where does the thyroid cancer warning come from?
The warning comes from animal studies, not from cancers seen in people taking the drug. According to the Wegovy label, semaglutide caused a dose-dependent and duration-dependent increase in thyroid C-cell tumors, both benign and cancerous, in mice and rats given it for their whole lives at exposures similar to those in patients.
The label states that it is unknown whether semaglutide causes these tumors, including medullary thyroid carcinoma (MTC), in humans. It also notes postmarketing reports of MTC in people taking liraglutide, an older drug in the same class, and says those reports are not enough to establish or exclude a causal link. The FDA put the finding in a boxed warning because MTC is serious and the human answer was not yet known.
MTC is a rare thyroid cancer that grows from C-cells, the cells that make the hormone calcitonin. It is a different disease from papillary thyroid cancer, the most common type.
What have studies in people found since?
Two large studies are cited most often, and they do not fully agree.
| Study | Who was studied | Main result |
|---|---|---|
| French nested case-control study, Diabetes Care, 2023 | 2,562 people with thyroid cancer matched to 45,184 controls, all with type 2 diabetes | One to three years of GLP-1 use linked to higher risk of all thyroid cancer (HR 1.58) and MTC (HR 1.78) |
| Scandinavian cohort, BMJ, 2024 | 145,410 new GLP-1 users in Denmark, Norway and Sweden compared with 291,667 new DPP-4 inhibitor users | No increase in thyroid cancer (HR 0.93, 95% CI 0.66 to 1.31); MTC estimate too imprecise to judge (HR 1.19, 0.37 to 3.86) |
The French study drew on national insurance data, and one common criticism is detection: people starting a new diabetes drug may get more checkups and imaging, which can uncover small cancers that were already there. The Scandinavian study compared GLP-1 users with users of another diabetes drug class to reduce that bias. Its average follow-up was 3.9 years, and it counted 76 thyroid cancers among the GLP-1 users, a rate of about 1.3 per 10,000 person-years.
Read together, the human data do not show a clear rise in thyroid cancer overall, and they cannot yet rule out a small increase in MTC specifically. That is exactly the uncertainty the label describes.
Why does a family history of MTC still rule it out?
Because the people with the most to lose from even a small risk are the ones already prone to MTC. The label lists a personal or family history of MTC, or multiple endocrine neoplasia type 2 (MEN 2), as a contraindication, meaning semaglutide should not be used at all.
MedlinePlus Genetics explains that MEN 2 affects an estimated 1 in 35,000 people, is caused by changes in the RET gene, and is inherited in an autosomal dominant pattern. Its most common sign is MTC, and in one subtype, familial MTC, thyroid cancer is the only feature. A relative’s history of “thyroid cancer” is therefore worth pinning down by type before you start.
Our page on who should not take semaglutide covers the other reasons to pass.
Should you get a calcitonin test or thyroid ultrasound first?
The label does not call for routine screening. It says routine calcitonin checks or thyroid ultrasounds are of uncertain value for catching MTC early in people on the drug, and that this kind of monitoring may lead to unnecessary procedures because calcitonin is not a very specific test and thyroid findings are common in the general population.
That changes if something turns up. The label says an elevated calcitonin, or a nodule felt on exam or seen on imaging, should be evaluated further. Our thyroid antibody test page explains a different, more common thyroid question that sometimes comes up in the same workup.
What symptoms should you report while taking it?
Tell your provider promptly about a lump or swelling in the neck, hoarseness that does not go away, trouble swallowing or shortness of breath; the label lists these as possible signs of a thyroid tumor. Each of these deserves an exam rather than a wait for your next check-in. Sudden or severe shortness of breath, or breathing trouble with chest pain, is not a clinic call: go to the emergency room or call 911.
How Ultimate Male screens before semaglutide
Before semaglutide is considered in our medical weight loss program, your provider reviews your personal and family history, including the type of any thyroid cancer and any MEN 2 diagnosis, along with your blood work before semaglutide or tirzepatide. If anything points toward MTC risk, a GLP-1 comes off the table and other parts of the plan take its place.
For a deeper look at the warning and the studies behind it, read our GLP-1 thyroid cancer warning article. If you are unsure about your family history, call a relative before your visit; that one detail decides more than any lab.
